Brokerages predict that Lantheus Holdings Inc (NASDAQ:LNTH) will announce earnings of $0.15 per share for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Lantheus’ earnings, with the highest EPS estimate coming in at $0.15 and the lowest estimate coming in at $0.14. Lantheus posted earnings per share of $0.12 in the same quarter last year, which suggests a positive year over year growth rate of 25%. The business is expected to announce its next quarterly earnings results on Monday, February 25th.
On average, analysts expect that Lantheus will report full-year earnings of $0.86 per share for the current financial year. For the next fiscal year, analysts anticipate that the company will post earnings of $0.99 per share, with EPS estimates ranging from $0.95 to $1.03. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Lantheus.
Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, October 30th. The medical equipment provider reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.06. Lantheus had a net margin of 36.75% and a return on equity of 83.95%. The business had revenue of $88.90 million during the quarter, compared to the consensus estimate of $83.53 million. During the same quarter last year, the company posted $0.24 earnings per share. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year.
Several equities analysts have recently weighed in on LNTH shares. Credit Suisse Group reduced their target price on shares of Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, August 2nd. BidaskClub upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a research note on Thursday, August 2nd. ValuEngine downgraded shares of Lantheus from a “hold” rating to a “sell” rating in a research note on Wednesday, October 31st. Wells Fargo & Co reduced their target price on shares of Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 2nd. Finally, Zacks Investment Research downgraded shares of Lantheus from a “hold” rating to a “sell” rating in a research note on Saturday, August 4th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $22.67.
LNTH opened at $14.96 on Friday. The stock has a market capitalization of $587.74 million, a PE ratio of 14.96, a price-to-earnings-growth ratio of 3.55 and a beta of 1.36. The company has a debt-to-equity ratio of 4.76, a current ratio of 3.50 and a quick ratio of 2.87. Lantheus has a twelve month low of $12.59 and a twelve month high of $24.45.
Several institutional investors and hedge funds have recently bought and sold shares of LNTH. Bank of Montreal Can purchased a new position in shares of Lantheus in the second quarter worth about $2,427,000. James Investment Research Inc. purchased a new position in Lantheus during the second quarter valued at approximately $1,289,000. Acadian Asset Management LLC purchased a new position in Lantheus during the second quarter valued at approximately $829,000. OLD National Bancorp IN purchased a new position in Lantheus during the second quarter valued at approximately $263,000. Finally, Eqis Capital Management Inc. grew its stake in Lantheus by 16.1% during the second quarter. Eqis Capital Management Inc. now owns 113,171 shares of the medical equipment provider’s stock valued at $1,647,000 after acquiring an additional 15,677 shares in the last quarter. Hedge funds and other institutional investors own 90.73% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.
See Also: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.